Latest Articles
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive
Published: Dec. 3, 2024, 5:11 p.m.
Aspira Women's Health Secures $2M ARPA-H Grant for AI-Powered Endometriosis Test | AWH Stock News - StockTitan
Aspira Women's Health Secures $2M ARPA-H Grant for AI-Powered Endometriosis Test | AWH Stock News StockTitan
Published: Dec. 3, 2024, 1 p.m.
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Investor Relations | Karyopharm Therapeutics
Karyopharm Therapeutics Provides Endometrial Cancer Program Update Investor Relations | Karyopharm Therapeutics
Published: Dec. 3, 2024, 12:01 p.m.
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Kilgore News Herald
Karyopharm Therapeutics Provides Endometrial Cancer Program Update Kilgore News Herald
Published: Dec. 3, 2024, noon
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - PR Newswire
Karyopharm Therapeutics Provides Endometrial Cancer Program Update PR Newswire
Published: Dec. 3, 2024, noon
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Longview News-Journal
Karyopharm Therapeutics Provides Endometrial Cancer Program Update Longview News-Journal
Published: Dec. 3, 2024, noon
Karyopharm Delays Endometrial Cancer Program Update Amid FDA Discussions | KPTI Stock News - StockTitan
Karyopharm Delays Endometrial Cancer Program Update Amid FDA Discussions | KPTI Stock News StockTitan
Published: Dec. 3, 2024, noon
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast
Hutchmed endometrial cancer treatment gets conditional approval in China ShareCast
Published: Dec. 3, 2024, 10:28 a.m.
NMPA greenlights new endometrial cancer therapy By Investing.com - Investing.com Australia
NMPA greenlights new endometrial cancer therapy By Investing.com Investing.com Australia
Published: Dec. 3, 2024, 10:15 a.m.
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire
Published: Dec. 3, 2024, 10:01 a.m.
Link copied to clipboard!